Impact of the Addition of Metformin to Abiraterone in Metastatic Prostate Cancer Patients
The purpose of this study is to assess the impact of the addition of metformin to abiraterone on survival in patients with metastatic prostate cancer
Metastatic Prostate Cancer
DRUG: Metformin
progression free survival, at 12 weeks
overall survival, up to 2 years
progression free survival at 24 weeks, at 24 weeks|progression free survival, up to 24 weeks|psa response, at 12 weeks|number of adverse events according to the NCI CTCAE v4.0, up to 24 weeks
The purpose of this study is to assess the impact of the addition of metformin to abiraterone on survival in patients with metastatic chemotherapy-naive prostate cancer